Key Highlights

IscAlert™ is a ground-breaking, patented and proven solution

  • Continuous pCO2 monitoring with accurate real-time readings.

  • The tissue pCO2 is a parameter which increases significantly during the early and reversible stages of ischemia. Monitoring of local tissue pCO2 provides the ability to identify the onset of ischemic events before irreversible injury occurs.

  • Potential to be used on millions of patients and could help improve quality of patient monitoring and reduce hospital costs.

  • Received funding from the European Union (European Innovation Council), the Norwegian Research Council and Innovation Norway.

CE mark and FDA clearance

  • Our first clinical trial was completed in June 2022 with excellent results.

  • We are presently undergoing the certification process to obtain the CE mark for IscAlert™ in compliance with the Medical Device Regulation (MDR) 2017/745.

  • Additionally, we are preparing to submit a 510(k) application to obtain FDA clearance for IscAlert™.

Untapped global potential for products that detect ischemia

  • There are no benchmark or comparable devices to IscAlert, meeting the so far unmet medical need to measure the pCO2 in tissue.

Multi-talented and highly educated team

  • Management and key employees with track record of achieving CE Mark and FDA approval.

  • 22 employees. Approx. 65% of employees holds a PhD or MSc degree.

Description of the innovation

Ischemia is a restriction of blood supply to tissues, causing a shortage of oxygen, reduced availability of nutrients and inadequate removal of metabolic wastes, eventually leading to cell death. If detected early, ischemia is highly preventable, however, there is currently no sensor system available for continuous accurate real time detection of ischemia.

IscAlert is a patented micro sensor system developed for detection of pCO2 in tissue. The tissue pCO2 is a parameter which increases significantly during the early and reversible stages of ischemia, a common consequence of illness, injury and surgery that is suffered by a large numbers of patients globally.

IscAlert innovatively detects altered pCO2, a key indicator of ischemia, thereby addressing a large and unmet medical need.

Partnerships

Our technology will bring added value to several medical areas. We welcome partnering initiatives from healthcare companies with attractive distribution networks both regionally and globally.

Please contact Sales and Marketing Lead, Jon Sigurd Syvertsen, jon.sigurd@sensocure.no, to explore partnership opportunities.

Investor Relations

Please contact CEO, Trond Herje, for investor related questions.

Email: trond@sensocure.no

Value Proposition for Sensocure AS

 

  • Company Overview: Sensocure AS specializes in developing groundbreaking biomedical sensors for healthcare, including IscAlert™, the world's first implantable microsensor for real-time, continuous monitoring of tissue pCO2, and early detection of an increase in pCO2 in tissues which occur during the initial, reversible stages of ischemia.

  • Innovation and Technology: IscAlert™ represents a revolutionary advancement in medical technology, providing surgeons and healthcare organizations with a user-friendly, fast, robust, and cost-effective real-time monitoring device for early detection of pCO2 increase in tissues.

  • Patient-Centric Approach: Sensocure's mission is driven by the urgent need to address the challenge of late detection of organ injuries. IscAlert™ offers a solution by providing early, accurate, and real-time monitoring, which ultimately may improve patient outcomes and reduced risk of irreversible ischemic events.

  • Quality and Reliability: Sensocure is committed to delivering high-quality and reliable products like IscAlert™, which directly addresses the critical medical need for real-time monitoring of tissues at risk of ischemia. This could enhance patient safety and well-being.

  • Ethical and Social Responsibility: Sensocure recognizes the significant impact of early ischemia detection in preventing organ damage and improving patient care. This innovative technology aligns with the ethical principle of beneficence in healthcare, which emphasizes the importance of reducing harm and the burdens of disease and suffering.

  • Sustainability and Future Focus: Sensocure is dedicated to ongoing research and development efforts aimed at advancing biomedical sensor technology, with IscAlert™ leading the way in addressing unmet medical needs and shaping the future of healthcare.

  • Competitive Market Engagement: IscAlert™ fills a crucial gap in existing medical solutions by offering real-time monitoring of pCO2, aligning with Sensocure's commitment to providing innovative and effective healthcare solutions in a competitive market landscape.

  • Sensocure recognizes the importance of its stakeholders and aims to foster strong relationships by developing innovative products like IscAlert™. This technology has the potential to enhance patient care through early detection of ischemia, which may lead to more timely interventions. While further research is needed to quantify its impact, IscAlert™ could potentially contribute to optimizing healthcare resource allocation and improving overall patient management in cases of ischemia.